

## Neurotech to present at NWR Virtual Healthcare Conference

**Neurotech International Limited (ASX: NTI)** ("Neurotech" or "the Company"), a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, today is pleased to announce that it will present at the NWR Virtual Healthcare Conference.

Executive Director Dr Thomas Duthy will present at **9:40am AEDT on Thursday 21 March 2024**.

Shareholders, investors and interested parties are encouraged to register to attend the presentation at the following link:

[https://us02web.zoom.us/webinar/register/WN\\_ns7L6xhBT7e5Ouzo8\\_2Sjg](https://us02web.zoom.us/webinar/register/WN_ns7L6xhBT7e5Ouzo8_2Sjg)

A recording will be available at the above link shortly after the conclusion of the live session, and the replay will also be available via the Company's website and social media channels.

Questions can be submitted on the day or sent in advance to [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

For more information please visit: <https://nwrcommunications.com/healthconf>

### Authority

This announcement has been authorised for release by the Board of Neurotech International Limited.

### Further Information

Dr Thomas Duthy  
Executive Director

[td@neurotechinternational.com](mailto:td@neurotechinternational.com)

+61 (0)402 493 727

### About Neurotech

**Neurotech International Limited (ASX:NTI)** is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders. Neurotech has completed a Phase I/II clinical trial in Autism Spectrum Disorder (ASD), which demonstrated excellent safety and efficacy results at 28 days, 20 weeks and 52 weeks of treatment with NTI164. The Company has commenced a Phase II/III randomised, double-blind, placebo-controlled clinical trial in ASD, and completed a Phase I/II trial in Rett Syndrome and in Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS. In addition, Neurotech has received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.